Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

SPRO vs ITRM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SPRO Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–2 Matrix Metrics)

SPRO Overall Winner 6-Pillar Tally: SPRO 3 – 2 ITRM (1 Tie) Matrix Metrics: SPRO 5 – 2 ITRM

As of Nov 20, 2026, Spero Therapeutics, Inc. (SPRO) is the stronger overall head-to-head candidate over Iterum Therapeutics plc Ordinary Share (ITRM) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SPRO carries a Unified Composite Score of 44.8/100 (HOLD) at $0.74 (N/M Forward P/E, 16.9% operating margin), whereas ITRM carries 50.5/100 (HOLD) at $0.03 (N/M Forward P/E, -1982.3% operating margin).

  • Composite vs. Pillar Nuance: While ITRM currently prints a higher short-term Unified Composite Score (50.5/100 HOLD vs. SPRO 44.8/100 HOLD), SPRO captures the overall institutional head-to-head verdict (5–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (16.9% vs. -1982.3% operating margin) and revenue trajectory (-95.6% vs. -100.0% YoY).
  • Technical & Structure Timing Caution: SPRO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 22.5); meanwhile ITRM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SPRO vs ITRM
SPRO NASDAQ Head-to-Head Winner
Spero Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$0.74
-10.2% 1D
Market Cap $46.2M
TTM Revenue $42M
Forward P/E N/M
Beta / 30D Vol 1.84β · 60% Vol
Unified Composite Score
44.8 / 100 HOLD
Tech 25.0 Fund 46.0 Flow 66.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.6%), weak momentum, RSI 23
RSI-14: 22.5 · SMA20: $1.01 · SMA50: $1.11
ITRM NASDAQ
Iterum Therapeutics plc Ordinary Share
Pharmaceutical Preparations
$0.03
-57.39% 1D
Market Cap $3.8M
TTM Revenue $390,000
Forward P/E N/M
Beta / 30D Vol 1.61β · 508% Vol
Unified Composite Score
50.5 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 50.0 Mom 75.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -23.9%), weak momentum, RSI 26
RSI-14: 25.9 · SMA20: $0.15 · SMA50: $0.23

6-Pillar Scorecard Institutional Category Breakdown (SPRO 3 – 2 ITRM)

Columns: Metric · SPRO · ITRM
1. Valuation Multiples ITRM
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 9.6x
2. Growth & Scale SPRO
Revenue Growth (YoY) -95.6% -100.0%
Earnings Growth (YoY) +75.3% +0.0%
TTM Revenue (USD) $42M $390,000
Market Cap $46.2M $3.8M
3. Profitability & Quality SPRO
Gross Margin 7.4% 29.7%
Operating Margin 16.9% -1982.3%
Net Profit Margin -71.0% 0.0%
Return on Equity (ROE) -216.4% -555.7%
4. Balance Sheet & Cash Flow SPRO
Cash Generation (TTM) -$40M -$19M EBITDA
Cash Flow Margin -97.3% N/A
Net Cash / Leverage $106M Net Cash -555.7% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ITRM
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 176.6% (46th %ile) N/A (N/A)
Put/Call OI Skew 5.37x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SPRO (5) vs ITRM (2)
Institutional Metric SPRO ITRM Criterion Row Edge
Market Capitalization
Scale
$46.2M $3.8M Larger Scale SPRO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-95.6% -100.0% Higher Growth SPRO
Operating Margin (TTM)
Profitability
16.9% -1982.3% Higher Margin SPRO
Net Profit Margin
Profitability
-71.0% 0.0% Higher Margin ITRM
Return on Equity (ROE)
Capital Efficiency
-216.4% -555.7% Higher ROE SPRO
52-Week Range Position
Momentum
0% ($1–$3) 0% ($0–$1) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
1.84β · 60% Vol 1.61β · 508% Vol Lower Realized Risk SPRO
Unified Institutional Score
Composite Signal
44.8 / 100 (HOLD) 50.5 / 100 (HOLD) Higher Composite ITRM
Trailing 12M Revenue (USD)
Operating Scale
$42M $390,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
7.4% 29.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 9.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$40M ($106M Net Cash) -$19M EBITDA (-555.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SPRO +96.23 pp
SPRO: +6.85% · ITRM: -89.38%
3M Horizon SPRO +91.36 pp
SPRO: +1.74% · ITRM: -89.62%
6M Horizon SPRO +90.53 pp
SPRO: -1.68% · ITRM: -92.21%
1Y Horizon SPRO +90.53 pp
SPRO: -1.68% · ITRM: -92.21%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SPRO vs ITRM. Trailing 12-month operating profitability (SPRO 16.9% vs ITRM -1982.3%) and valuation multiples (SPRO N/M vs ITRM N/M Forward P/E) are benchmarked directly in Pillar 4 below.

SPRO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$42M
Gross Margin7.4%
Op. Margin16.9%
ROE / Fwd P/E-216.4% · N/M
ITRM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$390,000
Gross Margin29.7%
Op. Margin-1982.3%
ROE / Fwd P/E-555.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SPRO BREAKDOWN
118d in phase · OBV DISTRIBUTION
Current IV 176.6%
IV Percentile 46th %ile
Put/Call OI Skew 5.37x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact SPRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ITRM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ITRM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SPRO Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $46.2M market capitalization and 16.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ITRM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.8M market capitalization and -1982.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SPRO vs ITRM Key Questions & Quantitative Answers

As of Nov 20, 2026, Spero Therapeutics, Inc. (SPRO) is the stronger overall head-to-head candidate over Iterum Therapeutics plc Ordinary Share (ITRM) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SPRO carries a Unified Composite Score of 44.8/100 (HOLD) at $0.74 (N/M Forward P/E, 16.9% operating margin), whereas ITRM carries 50.5/100 (HOLD) at $0.03 (N/M Forward P/E, -1982.3% operating margin). Composite vs. Pillar Nuance: While ITRM currently prints a higher short-term Unified Composite Score (50.5/100 HOLD vs. SPRO 44.8/100 HOLD), SPRO captures the overall institutional head-to-head verdict (5–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (16.9% vs. -1982.3% operating margin) and revenue trajectory (-95.6% vs. -100.0% YoY). Technical & Structure Timing Caution: SPRO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 22.5); meanwhile ITRM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SPRO leads the Growth & Scale pillar: SPRO posts -95.6% YoY revenue growth and +75.3% YoY earnings growth on $42M TTM revenue (7.4% gross margin, 16.9% operating margin), compared with ITRM at -100.0% YoY revenue growth and +0.0% YoY earnings growth on $390,000 TTM revenue (29.7% gross margin, -1982.3% operating margin). On trailing 12-month operating scale, SPRO generates $42M in USD-normalized revenue versus $390,000 for ITRM. In operating R&D and SG&A reinvestment, SPRO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ITRM.

ITRM screens cheaper on headline valuation multiples. SPRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (-97.3% FCF margin), whereas ITRM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.6x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SPRO (-216.4% ROE) versus ITRM (-555.7% ROE) capital efficiency.

In options market volatility and institutional positioning, SPRO carries 176.6% implied volatility (46th %ile, Balanced (25th–60th %ile)), a 5.37x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.84β · 60% Vol realized risk). By comparison, ITRM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.61β · 508% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.